We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
- Authors
Blanke, Charles D; Demetri, George D; von Mehren, Margaret; Heinrich, Michael C; Eisenberg, Burton; Fletcher, Jonathan A; Corless, Christopher L; Fletcher, Christopher D M; Roberts, Peter J; Heinz, Daniela; Wehre, Elisabeth; Nikolova, Zariana; Joensuu, Heikki
- Abstract
The outcome of patients diagnosed with advanced gastrointestinal stromal tumor (GIST) and treated long-term with imatinib mesylate is unknown. A previous report of a randomized phase II trial of imatinib mesylate in patients with incurable GIST detailed high response rates at both the 400 and the 600 mg/d dose levels. We conducted a long-term analysis of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 4, p620
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.13.4403